---
title: "Psilocybin (COMP360) in Treatment-resistant depression: COMP003"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: COMP003. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 41 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence/comp003"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: COMP003

<a id="heading-3.1.5"></a>

## 3.1.5 COMP003

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Safety, tolerability, and efficacy of COMP360 adjunctive to an SSRI

> “This phase II, exploratory, international, fixed-dose, open-label study explored the safety, tolerability, and efficacy of a synthetic form of psilocybin (investigational drug COMP360) adjunct to a selective serotonin reuptake inhibitor in participants with TRD.”
> “With the development of psilocybin specifically as a treatment for TRD, it is important to test the impact of chronic antidepressant treatment on the antidepressant effects of psilocybin.”
> “This outcome will inform whether it is necessary to withdraw people from antidepressant drugs prior to administering psilocybin for a safe or therapeutic effect.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Study period and sites in Ireland and the United States

> “This was a phase II, exploratory, fixed-dose, open-label study conducted between August 2020 and September 2021.”
> “The protocol was approved by ethics committees at two sites located in Ireland and the United States (US): the Clinical Research Ethics Committee of the Cork Teaching Hospitals (CREC), and the Advarra Center for IRB Intelligence (CIRBI).”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.2-2"></a>

#### Registry dates and locations

| Field | Registry entry |
| --- | --- |
| Study start (actual) | “2020-08-10” |
| Primary completion (actual) | “2021-10-14” |
| Study completion (actual) | “2021-10-14” |
| United States site | “Kadima Neuropsychiatry Institute” |
| Ireland site | “Sheaf House, Tallaght Hospital” |

Source: [ClinicalTrials.gov NCT04739865](https://clinicaltrials.gov/study/NCT04739865)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Open-label, single-arm, fixed-dose design

> “This trial explored the safety and efficacy of a single dose of 25 mg of the investigational drug COMP360, a proprietary pharmaceutical-grade synthetic psilocybin formulation, optimized for stability and purity, adjunct to an antidepressant drug in participants experiencing a current episode of treatment-resistant MDD (EudraCT number: 2018 002377; Clinicaltrials.gov identifier: NCT04739865).”
> “COMP360 was supplied by the sponsor, COMPASS Pathfinder Ltd (a subsidiary of COMPASS Pathways plc), London, UK.”
> “The sponsor supervised the study which was conducted by a contract research organization (Worldwide Clinical Trials, Nottingham, UK, and North Carolina, US).”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.3-2"></a>

#### Screening, administration, and follow-up periods

> “Eligible participants entered the screening period and attended the clinic weekly for three weeks prior to the psilocybin administration session.”
> “Participants were followed up for three weeks to monitor safety and efficacy.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.3-3"></a>

#### Recruitment alongside the phase 2b trial

> “Participants entered this study having been previously pre-screened for our phase IIb clinical trial (COMP 001), which was not an open label study, and the current trial (COMP 003) simultaneously.”
> “In COMP 001, 428 patients were screened and 233 were found to be eligible and underwent randomization having successfully withdrawn from any antidepressant drug as required by the protocol.”
> “Patients unable or unwilling to complete medication withdrawal at the two participating sites, or those who had a preference to be screened for COMP 003 instead, were considered for this study.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Inclusion criteria: treatment-resistant episode of major depressive disorder

> “This study recruited adults aged 18 years or older who were outpatients and referred by practitioners from specialized psychiatric services or word of mouth from primary care services.”
> “Participants were experiencing TRD, defined by meeting the Diagnostic and Statistical Manual of Mental Disorders (5th edition) criteria of single or recurrent episode of MDD (if first single episode, duration >3 months ≤2 years was required) without psychotic features and with at least moderate symptom severity (Hamilton Depression Rating Scale, 17 item [HAM-D-17] >18) at Screening and Baseline, and having failed to respond to an adequate dose and duration (>8 weeks) of two to four pharmacological treatments for the current episode, including their current SSRI”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.4-2"></a>

#### Inclusion criteria: stable treatment with a single SSRI

> “Participants were taking a locally approved therapeutic dose of a single SSRI with at least 75% adherence for a minimum of six weeks prior to taking part and were asked to continue this treatment for the duration of the study.”
> “Permitted SSRIs included citalopram, escitalopram, fluoxetine, paroxetine, sertraline, vilazodone, and vortioxetine.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.4-3"></a>

#### Exclusion criteria: psychiatric comorbidity, suicide risk, and other antidepressants

> “Participants taking multiple antidepressant therapies were excluded.”
> “Participants experiencing a major comorbid psychiatric disorder or suicide risk were excluded based on clinical assessment, medical records, the Mini International Neuropsychiatric Interview (version 7.0.2), the McLean screening instrument for borderline personality disorder, and the Columbia-Suicide Severity Rating Scale (C-SSRS)”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.4-4"></a>

#### Exclusion criteria in the registry record

> “Prior electroconvulsive therapy and/or ketamine for current episode.”
> “Ongoing use of an antidepressant medication, including augmentation or combination therapies, other than a single SSRI”
> “Significant suicide risk as defined C-SSRS within the past year”
> “Cardiovascular conditions”
> “Seizure disorder.”

Source: [ClinicalTrials.gov NCT04739865](https://clinicaltrials.gov/study/NCT04739865)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Single 25 mg dose during a monitored session

> “The administration session (Day 1) consisted of a single administration of psilocybin 25 mg which could be administered to up to six participants in different rooms simultaneously.”
> “Each participant was accompanied by a lead therapist, with whom they had completed preparation, for the six- to eight-hour session to ensure physical and psychological safety and encourage the participant to remain attentive to the natural unfolding of their subjective experience, while avoiding active guidance.”
> “An assisting therapist was available within the vicinity to step in at any time if the lead therapist needed to leave or additional support was required, and a study psychiatrist was on site.”
> “Blood pressure was monitored continuously using a finger cuff device.”
> “Participants wore eyeshades and headphones with a specifically designed playlist of music to assist in directing their attention internally.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.5-2"></a>

#### Preparation and integration sessions

> “Preparation for the psilocybin experience was conducted by a therapist who was trained by the sponsor through a specially devised program”
> “Preparation took place over three sessions, during which the therapist built trust with the participant, explained the trial design and procedures, provided psychoeducation, and helped to prepare the participant for the psilocybin experience.”
> “At Day 2 and Week 1 following administration, participants completed an integration session with their lead therapist who encouraged them to derive their own solutions and insights from the psilocybin experience.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.5-3"></a>

#### Continued SSRI treatment and simultaneous sessions

> “All participants continued their SSRI medication throughout the follow-up period and to the end of the study (Week 3); two participants on escitalopram increased their dose (10–20 mg) during the study.”
> “Two psilocybin administration sessions (Day 1) involved simultaneous administration, where two participants were administrated at the same time (in separate rooms) in each session.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Montgomery-Åsberg Depression Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Primary endpoint definition and scale range

> “The primary efficacy end point was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from Baseline (Day -1) to three weeks post-psilocybin administration (Week 3)”
> “Total scores in the MADRS range from 0-60, with higher scores indicating greater severity of depression.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.6.1-2"></a>

##### Remote blinded independent rating

> “The MADRS was administered by a remote, blinded independent rater, following the structured interview guide”
> “at Baseline (Day -1), Day 2 and Weeks 1, 2, and 3 to ensure standardization of administration and questions (service was provided by Worldwide Clinical Trials).”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.6.1-3"></a>

##### Secondary endpoints: response, remission, and clinician global ratings

> “Key secondary end points included the proportion of participants with a response (defined as a ≥50% improvement in MADRS total score from Baseline) and remission (defined as a MADRS total score ≤10) at Week 3, change from Baseline in Clinical Global Impression–Severity (CGI-S) score at Week 3”
> “The CGI-S is a 7-point rating scale of severity based on clinical judgment.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### No formal sample size calculation

> “No formal sample size calculations were performed for this study.”
> “Nineteen participants were dosed and the mean Baseline MADRS total score was 31.7 (SD = 5.77).”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.7.1-2"></a>

##### Registry enrollment

| Field | Registry entry |
| --- | --- |
| Enrollment (actual) | “19” |

Source: [ClinicalTrials.gov NCT04739865](https://clinicaltrials.gov/study/NCT04739865)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Safety, full analysis, and per-protocol sets

> “Safety analyses were performed on the safety analysis set which included all participants who received psilocybin.”
> “Efficacy analyses were performed on the full analysis set which included all participants who received psilocybin and had at least one post-Baseline efficacy assessment.”
> “All enrolled participants were included in the safety and full analysis sets and one participant was excluded from the per- protocol analysis set due to violation of exclusion criterion two: Prior electroconvulsive therapy and/or ketamine for current episode”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.7.2-2"></a>

##### Descriptive analysis and missing data

> “There was no imputation for missing efficacy data and the observed data were used in statistical analyses.”
> “The primary efficacy end point (change from Baseline to Week 3 in the MADRS total score) was evaluated with the use of descriptive summaries using statistics for continuous variables.”
> “Similarly, the secondary and exploratory efficacy end points were also summarized descriptively.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Enrolled, dosed, and completed

> “Nineteen out of 24 enrolled participants with TRD were dosed and completed the study - there were no post-treatment withdrawals.”
> “The stable and ongoing SSRIs included sertraline, escitalopram, fluoxetine, vilazodone, paroxetine, and citalopram”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Demographic and clinical characteristics, safety analysis set

| Characteristic | COMP360 25 mg + SSRI (N = 19) |
| --- | --- |
| Female, n (%) | “13 (68.4)” |
| Age, years, mean (SD) | “42.2 (10.80)” |
| Race, White, n (%) | “15 (78.9)” |
| Body mass index, kg/m2, mean (SD) | “26.26 (6.521)” |
| Duration of current episode 1 year to <2 years, n (%) | “13 (68.4)” |
| Duration of current episode >2 years, n (%) | “3 (15.8)” |
| Failed treatments in current episode: 2, n (%) | “12 (63.2)” |
| Failed treatments in current episode: 3 or 4, n (%) | “7 (36.8)” |
| Ongoing sertraline, n (%) [min dose, max dose] | “6 (31.6) [50 mg, 200 mg]” |
| Ongoing escitalopram, n (%) [min dose, max dose] | “6 (31.6) [5 mg, 20 mg]” |
| Ongoing fluoxetine, n (%) [min dose, max dose] | “3 (15.8%) [20 mg, 80 mg]” |
| Ongoing vilazodone, n (%) [min dose, max dose] | “2 (10.5%) [20 mg, 40 mg]” |
| Ongoing paroxetine, n (%) [dose] | “1 (5.3%) [60 mg]” |
| Ongoing citalopram, n (%) [dose] | “1 (5.3%) [20 mg]” |
| Duration of SSRI treatment prior to Baseline, months, mean (SD) | “14.68 (13.213)” |
| MADRS total score, mean (SD) | “31.7 (5.77)” |
| MADRS moderate (20 to 30), n (%) | “7 (36.8)” |

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.2-2"></a>

##### Depression severity and episode duration at baseline

> “The length of current episode of depression was greater than one year for 84.2% of participants, and 36.8% had experienced 3 or 4 treatment failures.”
> “At Baseline the MADRS total score was classified as severe (total score ≥31) for 57.9% of participants and the mean MADRS total score was 31.7 (SD = 5.77)”
> “At Baseline the mean CGI-S score was 4.3 (SD = 0.99) which falls into the ‘moderately ill’ range (score = 4).”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Primary endpoint: MADRS change from baseline at Week 3

> “The mean MADRS total score at Week 3 was 16.8 (95% confidence interval [CI], 11.2–22.4) which equated to a clinically meaningful mean change from Baseline of −14.9 (95% CI, −20.7 to −9.2).”
> “This improvement was apparent at Day 2 and maintained throughout the three-week follow-up”
> “The results from per-protocol analysis of the primary end point were consistent with the full analysis set.”
> “A reduction in every item in the MADRS was apparent from Baseline to Week 3”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.3-2"></a>

##### MADRS response and remission

> “Response (≥50% reduction from Baseline MADRS total score) at Week 3 was evident in eight (42.1%) participants and was sustained throughout the follow-up period for 63.2% at Day 2, and 57.9% at Weeks 1 and 2.”
> “The same 42.1% of participants who were responders at Week 3 were also remitters (MADRS total score of ≤10) at Week 3.”
> “Remission rates remained high throughout the follow-up period for 52.6% at Day 2, 47.4% at Week 1, and 42.1% at Week 2”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.3-3"></a>

##### Clinician global impression of severity and improvement

> “The mean CGI-S score at Week 3 was 2.9 (SD = 1.84) which equates to a −1.3 (SD = 1.29) change from Baseline.”
> “Proportion of responders on the CGI-S were 42.1% at Day 2, 63.2% at Week 1, 57.9% at Week 2, and 52.6% at Week 3”
> “Fourteen participants (73.7%) were considered at least minimally improved (CGI-I score ≤3) by clinicians from Baseline to Week 3 and seven participants (36.8%) were considered responders (score or 1 or 2) at Week 3.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.3-4"></a>

##### Authors' comparison with the phase 2b trial

> “in fact, the response and remission rates were higher in the current study (42% response and remission rates at Week 3 verses 37% and 29%, respectively).”
> “This indicates that antidepressant drug withdrawal is not a prerequisite for a therapeutic response to psilocybin in this patient group, despite most previous trials including withdrawal as a standard procedure”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.3-5"></a>

##### Acute psychedelic experience on the Five-Dimensional Altered States of Consciousness questionnaire

> “Alterations of consciousness on the 5D-ASC were observed in every dimension including visual restructuralization, oceanic boundlessness, reduction of vigilance, and to a lesser extent anxious ego dissolution and auditory alterations”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

##### Health-related quality of life: EQ-5D-3L and EQ-VAS

> “Participants’ EQ-5D-3L mean total score at Baseline was 0.51 (SD = 0.333) and improved by an average of 0.18 (SD = 0.310) by Week 3.”
> “The EQ-VAS mean score at Baseline was 49.0 (SD = 17.45) and improved by an average of 13.7 (SD = 18.09) by Week 3.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.4-2"></a>

##### Self-reported depression: QIDS-SR-16

> “The QIDS-SR-16 mean total score at Baseline was 16.5 (SD = 5.04), indicating severe depression, and decreased by an average of 6.9 (SD = 6.05) by Week 3 where the mean total score indicated mild depression.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.4-3"></a>

##### Anxiety and affect: GAD-7 and PANAS

> “The GAD-7 mean total score at Baseline was 12.9 (SD = 5.94) and decreased by an average of 4.1 (SD = 4.90) by Week 3, which is considered a clinically meaningful improvement in anxiety symptoms”
> “The mean Baseline score for positive affect was 19.3 (SD = 7.22) and increased by an average of 8.1 (SD = 10.58) by Day 2, and mean Baseline score for negative affect was 24.3 (SD = 10.26) and decreased by an average of 7.5 (SD = 6.79) by Day 2”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Treatment-emergent adverse events from Day 1 to Week 3, safety analysis set

| Period and event | Participants, n (%) | Events |
| --- | --- | --- |
| Overall: any TEAE | “12 (63.2)” | “17” |
| Overall: any severe TEAE | “2 (10.5)” | “2” |
| Overall: any serious TEAE | “0” | “0” |
| Day 1: any TEAE | “9 (47.4)” | “11” |
| Day 1: headache | “4 (21.1)” | “4” |
| Day 1: blood pressure increased | “3 (15.8)” | “3” |
| Day 1: dizziness | “1 (5.3)” | “1” |
| Day 1: dry mouth | “1 (5.3)” | “1” |
| Day 1: fall | “1 (5.3)” | “1” |
| Day 1: skin abrasion | “1 (5.3)” | “1” |
| After Day 1 to Week 3: any TEAE | “4 (21.1)” | “6” |
| After Day 1 to Week 3: headache | “2 (10.5)” | “2” |
| After Day 1 to Week 3: depression | “1 (5.3)” | “1” |
| After Day 1 to Week 3: diarrhea | “1 (5.3)” | “1” |
| After Day 1 to Week 3: palpitations | “1 (5.3)” | “1” |
| After Day 1 to Week 3: vertigo | “1 (5.3)” | “1” |

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.5-2"></a>

##### Onset, duration, and headache

> “Seventeen TEAEs were reported for 12 participants (63.2%), none of which were considered serious, or led to study withdrawal”
> “Eleven of these TEAEs, which were experienced in nine participants (47.4%), had an onset of Day 1 (psilocybin administration day), and eight resolved on the same day.”
> “The most common TEAE reported was headache (six events; six participants [31.6%]) which had an onset of Day 1 (n = 4) or Day 2 (n = 2) which were predominantly transient, reported as mild and moderate in five and one participants, respectively, and resolved on their own or with standard medication (paracetamol and ibuprofen) on the same day or day after.”
> “All TEAEs resolved before the end of the study (Week 3), and none had a duration exceeding seven days.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.5-3"></a>

##### Blood pressure increase treated with clonidine

> “Three participants had a TEAE of blood pressure increased which were considered related or possibly related to study treatment, two were severe and treated with clonidine.”
> “One of these patients experienced chest heaviness and headache (also relieved by clonidine).”
> “There were no specific parameters for administering clonidine and it was down to investigator discretion.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.5-4"></a>

##### Suicidal ideation and behavior

> “There were no reports of active suicidal ideation with plan or intent to act, attempts, or self-injurious behavior at Baseline or during the study and follow-up period”
> “During the follow-up period, one participant who was disappointed by their lack of response and quality of psychedelic experience invoked concern regarding their mental state during a conversation with their non-study therapist, which prompted the therapist to initiate an involuntary assessment of the participant at a local emergency department.”
> “After evaluation by a psychiatrist in the emergency department, the participant was deemed to not be a danger to themselves and not in need of hospital admission.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.8.5-5"></a>

##### Laboratory tests and electrocardiograms

> “There were no clinically meaningful shifts from Baseline in clinical laboratory tests.”
> “No participant had treatment-emergent clinically important ECG values or increases in QTcF interval from Baseline.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary: open-label single-arm design, small sample, short follow-up, blood pressure measurement, sponsor analysis

The authors state that the study was limited by its small size, open-label design and absence of a comparator, a sample that was not demographically diverse, and the exclusion of participants with high suicide risk or current hospitalization, and that the open-label design may have influenced participant expectations. Nineteen participants were dosed, no formal sample size calculation was performed, efficacy was summarized descriptively, and follow-up lasted three weeks. Blood pressure elevations were recorded with a finger cuff system that was not accurately calibrated. The sponsor performed the data review, interpretation, and post hoc analyses, and several authors are current or past employees of COMPASS Pathfinder. The authors state that the findings need confirmation in a larger, double-blind, comparator-controlled study.

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.9-2"></a>

#### Authors' stated limitations

> “The present study was limited by its small size, open-label design and absence of a comparator, the lack of a demographically diverse sample, and the exclusion of participants with high suicide risk or current hospitalization.”
> “It is possible that the open-label design influenced participant bias and expectations towards the study treatment, and definitive comparisons with studies that included a withdrawal from SSRIs is not necessarily valid.”
> “The findings will need to be confirmed in a larger, double-blind, comparator-controlled study.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.9-3"></a>

#### Blood pressure measurement

> “Unfortunately, we cannot give an accurate measure of the blood pressure elevation that undoubtedly occurred, because the finger cuff system was not accurately calibrated.”
> “but these specific instances were recorded with a system which may not have been properly calibrated and were not checked by conventional cuff auscultation.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.9-4"></a>

#### Follow-up duration

> “Future research should examine whether the outcomes of psilocybin as a monotherapy or as an adjunct to SSRIs remain comparable in a longer term follow up.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

<a id="topic-3.1.5.9-5"></a>

#### Sponsor role in analysis and interpretation

> “Review of the data, interpretation, and post-hoc statistical analyses and were performed by the sponsor.”
> “GMG, MC, LM, SM, HS, CS, SCS, JT, SW, and EM are current or past employees of COMPASS Pathfinder.”

Source: [Goodwin et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10425429/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
